首页> 外文期刊>Journal of Pharmacy and Pharmacology >Antihyperglycaemic and antioxidant effect of hyponidd, an ayurvedic herbomineral formulation in streptozotocin-induced diabetic rats.
【24h】

Antihyperglycaemic and antioxidant effect of hyponidd, an ayurvedic herbomineral formulation in streptozotocin-induced diabetic rats.

机译:Hyponidd的抗高血糖和抗氧化作用,一种链脲佐菌素诱导的糖尿病大鼠,是一种非草药的草药配方。

获取原文
获取原文并翻译 | 示例
       

摘要

Hyponidd is a herbomineral formulation composed of the extracts of ten medicinal plants ( Momordica charantia, Melia azadirachta, Pterocarpus marsupium, Tinospora cordifolia , Gymnema sylvestre, Enicostemma littorale, Emblica officinalis, Eugenia jambolana, Cassia auriculata and Curcuma longa). We have investigated hyponidd for its possible antihyperglycaemic and antioxidant effect in diabetic rats. Rats were rendered diabetic by streptozotocin (STZ) (45 mg kg(-1) body weight). Oral administration of hyponidd (100 mg kg(-1) and 200 mg kg(-1)) for 45 days resulted in significant lowered levels of blood glucose and significant increased levels of hepatic glycogen and total haemoglobin. An oral glucose tolerance test was also performed in experimental diabetic rats in which there was a significant improvement in blood glucose tolerance in the rats treated with hyponidd. Hyponidd administration also decreased levels of glycosylated haemoglobin, plasma thiobarbituric acid reactive substances, hydroperoxides, ceruloplasmin and alpha-tocopherol in diabetic rats. Plasma reduced glutathione and vitamin C were significantly elevated by oral administration of hyponidd. The effect of hyponidd at a dose of 200 mg kg(-1) was more effective than glibenclamide (600 microg kg(-1)) in restoring the values to near normal. The results showed that hyponidd exhibits antihyperglycaemic and antioxidant activity in STZ-induced diabetic rats.
机译:Hyponidd是一种植物性矿物配方,由十种药用植物的提取物组成(苦瓜,苦瓜,za藜,紫皮香,樟子松,樟子松,Emblica officinalis,Eugenia jambolana,Cursia auriculata)。我们已经研究了hyponidd在糖尿病大鼠中可能的抗高血糖和抗氧化作用。链脲佐菌素(STZ)(45 mg kg(-1)体重)使大鼠患糖尿病。口服给予皮下注射(100 mg kg(-1)和200 mg kg(-1))45天导致血糖水平显着降低,肝糖原和总血红蛋白水平显着提高。还对实验性糖尿病大鼠进行了口服葡萄糖耐量试验,其中用hyponidd治疗的大鼠的葡萄糖耐量显着改善。混合给药还降低了糖尿病大鼠中糖基化血红蛋白,血浆硫代巴比妥酸反应性物质,氢过氧化物,铜蓝蛋白和α-生育酚的水平。口服hyponidd可使血浆还原型谷胱甘肽和维生素C显着升高。将200 mg kg(-1)剂量的次ni酸的作用恢复到接近正常值比格列本脲(600 microg kg(-1))更有效。结果表明,hyponidd在STZ诱导的糖尿病大鼠中具有抗高血糖和抗氧化活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号